Cullinan Therapeutics, Inc.Cullinan Therapeutics, Inc.Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪717.90 M‬USD
−3.70USD
‪−153.16 M‬USD
‪26.34 M‬
Beta (1Y)
1.75

About Cullinan Therapeutics, Inc.

CEO
Nadim Ahmed
Headquarters
Cambridge
Employees (FY)
85
Founded
2016
FIGI
BBG00HW2DGQ4
Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where CGEM is featured.

Frequently Asked Questions

The current price of CGEM is 18.89 USD — it has increased by 13.32% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cullinan Therapeutics, Inc. stocks are traded under the ticker CGEM.
Cullinan Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
CGEM stock is 18.27% volatile and has beta coefficient of 1.75. Check out the list of the most volatile stocks — is Cullinan Therapeutics, Inc. there?
CGEM earnings for the last quarter are −0.91 USD per share, whereas the estimation was −0.92 USD resulting in a 1.22% surprise. The estimated earnings for the next quarter are −0.96 USD per share. See more details about Cullinan Therapeutics, Inc. earnings.
Yes, you can track Cullinan Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CGEM stock has risen by 4.89% compared to the previous week, the month change is a 14.00% rise, over the last year Cullinan Therapeutics, Inc. has showed a 78.38% increase.
CGEM net income for the last quarter is ‪−23.80 M‬ USD, while the quarter before that showed ‪−39.18 M‬ USD of net income which accounts for 39.25% change. Track more Cullinan Therapeutics, Inc. financial stats to get the full picture.
Today Cullinan Therapeutics, Inc. has the market capitalization of ‪813.51 M‬, it has decreased by 9.76% over the last week.
No, CGEM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CGEM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cullinan Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
CGEM reached its all-time high on Mar 10, 2021 with the price of 59.85 USD, and its all-time low was 7.30 USD and was reached on May 11, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 85.00 employees. See our rating of the largest employees — is Cullinan Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cullinan Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cullinan Therapeutics, Inc. stock shows the strong buy signal. See more of Cullinan Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cullinan Therapeutics, Inc. future price: according to them, CGEM price has a max estimate of 36.00 USD and a min estimate of 19.00 USD. Read a more detailed Cullinan Therapeutics, Inc. forecast: see what analysts think of Cullinan Therapeutics, Inc. and suggest that you do with its stocks.